Durvalumab (durva) after chemoradiotherapy (CRT) in unresectable, stage III, EGFR mutation-positive (EGFRm) NSCLC: A post hoc subgroup analysis from PACIFIC.

J Naidoo, SJ Antonia, YL Wu, BC Cho, P Thiyagarajah, H Mann, MD Newton, C Faivre-Finn

Research output: Contribution to journalMeeting Abstractpeer-review

Original languageEnglish
Number of pages1
JournalJournal of Clinical Oncology
Issue number16
Publication statusPublished - 1 Jun 2022

Cite this